In our recent alert announcing Valeant's
decision to in-license psoriasis candidate, brodalumab from AstraZeneca we commented that the
deal may suffer from a lack of manufacturing capacity for biologics.
AstraZeneca appears to be making a concerted effort to expand
manufacturing capacity potentially addressing this
Comments: Across the AstraZeneca/Medimmune
pipeline at least 6 mAbs may be in a position to launch in the near term
(Durvalumab, Moxetumomab and Tremelimumab
for oncology and brodalumab, Benralizumab and Tralokinumab for
immunology). New capacity will be required to meet this over demand.
Although it is unclear whether AstraZeneca will be responsible for
brodalumab manufacture under its deal with Valeant, today's new makes
it increasingly likely that it will be able to do so if necessary.
Furthermore until Amgen's recent decision to drop brodalumab it may have
even been the intent to manufacture commercial supply at the Colorado
site suggesting that processes are up and ready to rapidly meet demand
- AstraZeneca has recently invested $285M in
its Swedish biologics facility. Capacity at an existing Maryland site
is also to be expanded (see our original alert below)
- Now AstraZeneca has announced the purchase of a biologics bulk manufacturing facility from Amgen in Colorado
- AstraZeneca reportedly plans to start staffing the facility immediately to support refurbishment and infrastructure improvements
- Once complete, the site is expected to be operational and licensed for commercial production by late 2017
- The facility will eventually double AstraZeneca's biologics manufacturing capacity in the US.
For detailed analysis of immunology pipelines, R&D activity and commercial activity ask us about UpdatesPlus - sample 100 page reports available on request
Labels: astrazeneca, biologics, brodalumab, il-17, monoclonal antibody, psorisias, valeant